Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820965 | 0.92 | PRKCQ (0.56) | PRKCQSMN1; SMN2MAPTMAP4K4CDK1 | |
| SCHEMBL3812892 | 0.89 | PRKCQ (0.49) | PRKCQKMT2AMAPTMAP4K4CDK1 | |
| SCHEMBL3815982 | 0.89 | PRKCQ (0.48) | PRKCQKMT2AMAPTMAP4K4CDK1 | |
| SCHEMBL3812413 | 0.89 | PRKCQ (0.59) | PRKCQKMT2AMAPTNPC1MITF | |
| SCHEMBL3815999 | 0.88 | PRKCQ (0.50) | PRKCQKMT2AMAPTCYP3A4CYP2D6 | |
| SCHEMBL3812825 | 0.87 | KMT2A (0.57) | PRKCQKMT2ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL3814661 | 0.87 | PRKCQ (0.57) | PRKCQSMN1; SMN2MAPTMAP4K4CDK1 | |
| SCHEMBL3818551 | 0.86 | SMN1; SMN2 (0.47) | PRKCQKMT2ASMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL4484863 | 0.85 | PRKCQ (0.47) | PRKCQKMT2ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL3821325 | 0.84 | PRKCQ (0.49) | PRKCQKMT2ASMN1; SMN2MAPTCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1590334-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004067516-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885KMT2A 919/4885SMN1; SMN2 4262/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885KMT2A 73/4885SMN1; SMN2 4654/4885 |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCD | PRKCQ 2/4885KMT2A 2751/4885SMN1; SMN2 3661/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885KMT2A 1962/4885SMN1; SMN2 4592/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885KMT2A 73/4885SMN1; SMN2 4654/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885KMT2A 919/4885SMN1; SMN2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.